206 related articles for article (PubMed ID: 30811629)
21. Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma.
Mavropoulos JC; Aldabagh B; Arron ST
Semin Cutan Med Surg; 2014 Jun; 33(2):72-5. PubMed ID: 25085665
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
[No Abstract] [Full Text] [Related]
24. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
Que SKT; Zwald FO; Schmults CD
J Am Acad Dermatol; 2018 Feb; 78(2):249-261. PubMed ID: 29332705
[TBL] [Abstract][Full Text] [Related]
26. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.
Pezeshki S; Hemmati S; Rezaei N
Expert Rev Anticancer Ther; 2020 Oct; 20(10):819-822. PubMed ID: 32852235
[No Abstract] [Full Text] [Related]
27. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
28. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
29. Retrospective Investigation of Cutaneous Squamous Cell Carcinoma on the Lip Treated with Peplomycin Administered Through a Superficial Temporal Artery.
Fujimura T; Takahashi K; Kambayashi Y; Furudate S; Hidaka T; Kakizaki A; Watabe A; Haga T; Hashimoto A; Aiba S
Anticancer Res; 2017 Apr; 37(4):1885-1889. PubMed ID: 28373456
[TBL] [Abstract][Full Text] [Related]
30. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.
Trinh VA; Joseph J; Hwu WJ
Discov Med; 2018 Jan; 25(135):31-40. PubMed ID: 29466692
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
32. Rapid Life-Saving Response to Anti-PD-1 in a Solid Organ Transplant Recipient With Metastatic Cutaneous Squamous Cell Carcinoma: A Case Report and Review.
Antonelli JP; Quach M; Mahajan A; Pleva J; Ma VT
J Immunother; 2024 Jul-Aug 01; 47(6):216-219. PubMed ID: 38532708
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma.
Tsibris H; Lian C; Ho A
Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999581
[TBL] [Abstract][Full Text] [Related]
34. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
35. Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature.
Corneli P; Conforti C; Retrosi C; Vezzoni R; di Meo N; Piccolo V; Farinazzo E; Russo T; Magaton Rizzi G; Giuffrida R; Zalaudek I
Dermatol Ther; 2020 Mar; 33(2):e13250. PubMed ID: 32022968
[TBL] [Abstract][Full Text] [Related]
36. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
37. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
[TBL] [Abstract][Full Text] [Related]
38. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
[No Abstract] [Full Text] [Related]
39. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
[TBL] [Abstract][Full Text] [Related]
40. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]